+ In its most recent fiscal year the company generated revenue of $94,193.0M, split between prescription medicines distributed to wholesalers, hospitals, retailers and healthcare professionals, and devices sold into surgical, cardiovascular, orthopaedic and vision settings. It is a New Jersey–incorporated multinational whose operating subsidiaries span nearly all countries, supported by a large, glo

+ | Report Date | 2026-08-19 |

+ | Current Price | $271.11 |

+ | Rating | REDUCE |

+ | 12-Month Price Target | $189.25 |

+ Capital allocation is where the character of this business is clearest. The defining fact is the dividend: the company again raised its per-share payout during the year, extending a multi-decade, uninterrupted streak of consecutive annual increases that places it in the small cohort of true dividend aristocrats and makes the dividend the single most reliable component of shareholder return. Buybac

+ **§1.6.4 — Verdict.** Our conclusion is that the competitive position is genuinely wide and durable — anchored by scale, IP, category leadership and a fortress balance sheet — and should sustain premium, resilient operating margins over the long run even as individual franchises cycle through their patent lives. That durability is precisely why the business commands a defensive, quality rating. Bu

+ | Total OpEx excl. COGS ($M) | $40,525.0M | $40,472.0M | $37,399.0M | $40,546.0M | $38,650.0M |

+ | Revenue | -0.3% | 2.7% | - |

+ | EBITDA | 2.6% | 4.2% | - |

+ | Net Income | 14.3% | 12.7% | - |

+ | Diluted EPS | 17.9% | 14.9% | - |

+ | FCF | 4.7% | -0.5% | - |

+ | **Z-Score** | **2.00** | **1.88** | **1.88** |

+ **The Z-Score sits in the gray zone and drifts marginally lower — and this is a case where the model materially understates true credit quality.** At 1.88 in FY2025, down slightly from 2.00 in FY2023, the score falls in the model's 1.23–2.90 gray band rather than the safe zone. Taken at face value that reads as ambiguous credit — but the Altman model was calibrated to asset-turning manufacturers,

+ | Risk-Free Rate (10Y UST) | 4.72% | US Treasury daily yield curve |

+ | Beta (Levered) | 0.50 | Normalized — overrides raw market beta (see prose) |

+ | **Cost of Equity (Ke)** | **6.83%** | CAPM: Rf + β × (ERP + CRP) |

+ At 6.83%, Johnson & Johnson's cost of equity sits toward the low end of the large-cap universe — a fair reflection of its defensive, AAA-rated, globally diversified profile, but one that rests almost entirely on a single input. The risk-free rate of 4.72% and the equity risk premium of 4.23% are market-standard figures applied identically to every US large-cap; what distinguishes JNJ's cost of equ

+ We have deliberately overridden the market here, and the reader should understand exactly why. The market-observed betas are implausibly low across every measurement: our own 60-month price-history regression reads 0.245, and the independent five-year web reading is 0.23 — mutually corroborating, and both rejected outright. That regression window is dominated by the 2023–2025 talc-litigation whips

+ | Equity Weight (market value) | 95.9% |

+ | Debt Weight (market value) | 4.1% |

+ | **WACC** | **6.63%** |

+ At 95.9% equity and 4.1% debt on market values, JNJ is, for valuation purposes, effectively an all-equity enterprise. WACC of 6.63% is consequently almost entirely equity-driven; the after-tax cost of debt of 1.92%, though very low, carries negligible weight. In practical terms WACC is nearly identical to the cost of equity, which means every conclusion in this valuation inherits the beta judgment

+ The DCF uses a five-year explicit projection period followed by a terminal value. The cash-flow engine is built on **operating EBIT flowing to NOPAT**, deliberately clean of the "Other (income)/expense, net" line that has distorted JNJ's headline earnings — most acutely the sizeable non-cash talc reserve reversal recognized in FY2025, which never enters these projections. The terminal value is com

+ | Revenue Growth — each year | Base - 2pp | 3.5% (Y1) → 4.0% (Y5) | Base + 2pp |

+ | EBITDA Margin — each year | Base - 1pp | 34.0% (Y1) → 35.0% (Y5) | Base + 1pp |

+ | CapEx / Revenue | unchanged | 5.0% | unchanged |

+ | Exit EV/EBITDA Multiple | 13.5x | 13.5x | 13.5x |

+ | WACC | 6.63% | 6.63% | 6.63% |

+ *Note: Bear and Bull use the standard adjustments above (per the valuation-agent methodology), applied to every projection year. The resulting fair values appear in Section 6.2 ($188.55 / $271.83).*

+ The base-case revenue path — 3.5%, 4.5%, 5.0%, 4.5%, 4.0% — is deliberately not anchored to JNJ's reported three-year revenue CAGR, which is not a usable reference: the 2023 Kenvue separation severed the historical series and renders the headline multi-year growth figure meaningless. Instead the path is built on continuing-operations momentum and the product pipeline. Year 1 is held to 3.5% to abs

+ The base-case EBITDA margin rises gently from 34.0% in Year 1 to 35.0% by Year 5. The path assumes only modest operating leverage and favorable mix, not aggressive expansion: the loss of high-margin STELARA volume and IRA pricing pressure cap the upside in the early years, while pipeline scaling and MedTech mix support a slight lift later. The assumed band is broadly consistent with the operating

+ | Revenue ($M) | $94,193.0M | $97,489.8M | $101,876.8M | $106,970.6M | $111,784.3M | $116,255.7M |

+ | EBITDA ($M) | — | $33,146.5M | $35,147.5M | $36,904.9M | $39,124.5M | $40,689.5M |

+ | EBIT ($M) | — | $25,347.3M | $26,997.4M | $28,347.2M | $30,181.8M | $31,389.0M |

+ | NOPAT ($M) | — | $21,165.0M | $22,542.8M | $23,669.9M | $25,201.8M | $26,209.8M |

+ | Unlevered FCF ($M) | — | $23,760.0M | $25,160.4M | $26,369.7M | $28,073.9M | $29,250.4M |

+ | PV of UFCF ($M) | — | $22,282.4M | $22,128.2M | $21,749.4M | $21,715.0M | $21,217.9M |

+ | Sum of PV of UFCFs ($M) | $109,093.0M |

+ | Terminal Value — Perpetuity Growth ($M) | $725,677.1M |

+ | Terminal Value — Exit Multiple ($M) | $549,308.1M |

+ | Selected Terminal Value ($M) | $637,492.6M |

+ | PV of Terminal Value ($M) | $462,430.8M |

+ | **Enterprise Value ($M)** | **$571,523.7M** |

+ | **Equity Value ($M)** | **$543,299.7M** |

+ | **DCF Fair Value / Share (Base)** | **$225.44** |

+ | Upside / Downside vs. Current Price | -16.8% |

+ The bridge makes the terminal-method choice explicit. The perpetuity method produces a terminal value of $725,677.1M; the exit EV/EBITDA method, at 13.5x, produces the more conservative $549,308.1M. Both are legitimate. The perpetuity method is defensible for a stable compounder, but on JNJ it puts an outsized share of value in the terminal on a thin spread — the gap between the 6.63% discount rat

+ The price target is sensitive to both the discount rate and the terminal growth rate, and the grid below isolates that sensitivity for the **perpetuity leg** of the terminal value only. WACC increases **down** the rows; terminal growth increases **across** the columns. A crucial point of interpretation: the bolded central cell is the value of the *perpetuity method* at base assumptions (6.63% WACC

+ | WACC \ TGR | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |

+ |---|---|---|---|---|---|---|---|

+ | 4.6% | 305.4 | 349.9 | 411.3 | 501.6 | 647.2 | 921.5 | 1,630.0 |

+ | 5.1% | 266.5 | 299.6 | 343.3 | 403.6 | 492.2 | 635.0 | 904.1 |

+ | 5.6% | 236.1 | 261.6 | 294.1 | 336.9 | 396.1 | 483.0 | 623.1 |

+ | 6.1% | 211.6 | 231.7 | 256.7 | 288.6 | 330.7 | 388.7 | 474.0 |

+ | 6.6% | 191.5 | 207.7 | 227.4 | 252.0 | 283.3 | 324.5 | 381.5 |

+ | 7.1% | 174.6 | 187.9 | 203.9 | 223.3 | 247.3 | 278.0 | 318.6 |

+ | 7.6% | 160.3 | 171.4 | 184.5 | 200.2 | 219.2 | 242.8 | 273.0 |

+ | 8.1% | 148.0 | 157.4 | 168.3 | 181.2 | 196.5 | 215.2 | 238.4 |

+ | 8.6% | 137.3 | 145.3 | 154.5 | 165.3 | 177.9 | 193.0 | 211.3 |

+ The geography of the grid is the analysis. Because WACC rises down the rows and terminal growth rises across the columns, the highest values sit in the top-right corner (lowest discount rate, highest growth) and the lowest in the bottom-left. The current share price of $271.11 does not appear anywhere at or below the base assumptions: at the base 6.63% discount rate, the perpetuity leg only reache

+ We benchmark Johnson & Johnson against the two large-cap US pharmaceutical majors whose scale, R&D intensity, and therapeutic-area overlap make them the most defensible comparators: AbbVie Inc. and Merck & Co., Inc.. Both file US GAAP 10-Ks with December fiscal year-ends identical to JNJ's, so there is no period mismatch and no accounting-standard translation to caveat — the comparison is like-for

+ The single most important qualification is structural, not accounting. JNJ is a two-business company — Innovative Medicine (branded pharmaceuticals) plus MedTech (surgical, orthopaedics, cardiovascular, vision), the latter roughly a third of sales and carrying structurally lower gross and EBITDA margins and slower growth than branded drugs. AbbVie and Merck are, for practical purposes, pure-pharma

+ | AbbVie Inc. | ABBV | NYSE | 10-K | US GAAP | December | Pure-pharma; negative book equity and heavy acquisition-accounting charges make GAAP net income, ROE, D/E, and book value per share not meaningful — steer to EBIT/EBITDA, net-debt/EBITDA, and FCF. |

+ | Merck & Co., Inc. | MRK | NYSE | 10-K | US GAAP | December | Pure-pharma; FY2025 earnings are the cleanest of the three, but heavy Keytruda concentration and a ~2028 loss-of-exclusivity colour the growth read and the low multiple. |

+ *Source: Peer-company SEC filings (AbbVie FY2025 10-K; Merck FY2025 10-K); comparability notes in 5.7 — see Appendix A.1.*

+ | Metric | Johnson & Johnson | AbbVie Inc. | Merck & Co., Inc. |

+ | Revenue ($M) | $94,193.0M | $61,160.0M | $65,011.0M |

+ | Gross Margin | 67.9% | 70.2%ᵃ | 74.8% |

+ | EBITDA Margin | 34.8% | 38.0% | 41.6% |

+ | EBIT Margin | 26.8% | 24.6% | 32.6%ᵇ |

+ | Net Margin | 28.5%ᶜ | 6.9%ᵈ | 28.1% |

+ | FCF Margin | 20.9% | 29.1% | 19.0% |

+ *Source: Peer-company SEC filings (AbbVie FY2025 10-K; Merck FY2025 10-K); comparability notes in 5.7 — see Appendix A.1.*

+ *Footnotes: ᵃ AbbVie's gross margin is overstated versus JNJ and Merck because AbbVie reports acquired-intangible amortization on a separate line rather than within cost of sales. ᵇ Merck's EBIT/EBIT-margin is an analyst construction (no operating-income subtotal on the face), computed on the same basis as JNJ, so the JNJ-vs-Merck EBIT comparison is like-for-like. ᶜ JNJ's FY2025 net margin is flat

+ The disciplined read is to anchor on EBIT and EBITDA and to treat GAAP net margin as low-comparability across the entire set, because net income is distorted in three different directions. JNJ's FY2025 net margin of 28.5% is inflated by the reversal of a talc-litigation reserve — a non-cash, non-operating tailwind — and is not a clean read of underlying earnings power. AbbVie's 6.9% is the mirror

+ The operating lines tell the real story, and the most revealing feature is a crossover between EBIT and EBITDA. On EBIT margin, JNJ's 26.8% sits *above* AbbVie's 24.6% and below Merck's 32.6%. But on EBITDA margin the order flips against JNJ: JNJ's 34.8% falls below *both* AbbVie's 38.0% and Merck's 41.6%. The reason is AbbVie's amortization load. AbbVie's operating earnings are struck after a ver

+ *Source: JNJ FY2025 10-K (three-year statements) and prior filings; comparability notes in 5.7 — see Appendix A.1.*

+ JNJ's own five-year record confirms that the operating lines are the stable ones and the net line is the noisy one. Gross and EBITDA margins have held in a tight band across the period — evidence of a durable, mix-resilient cost structure. Net margin, by contrast, swings on litigation and separation accounting: it compressed through FY2023–FY2024 as the talc reserve was built and the Kenvue consum

+ | Metric | Johnson & Johnson | AbbVie Inc. | Merck & Co., Inc. |

+ | ROIC | 21.5%ᵍ | 15.1% | 18.0% |

+ | ROE | 35.0%ᵉ | —ᶠ | 36.9% |

+ | ROA | 14.1%ᵉ | 3.1% | 14.4% |

+ | Asset Turnover | 0.47x | 0.46x | 0.51x |

+ *Source: Peer-company SEC filings (AbbVie FY2025 10-K; Merck FY2025 10-K); comparability notes in 5.7 — see Appendix A.1.*

+ *Footnotes: ᵉ JNJ's FY2025 ROE and ROA are flattered by the same talc-reserve reversal that inflated net income; underlying returns are lower. ᶠ AbbVie's ROE is not meaningful — the company carries negative book equity (an accumulated deficit from Allergan goodwill and sustained buybacks), so a book-based return is reported as not meaningful rather than as a spurious figure. ᵍ JNJ's ROIC is the mo

+ All three companies earn returns on invested capital comfortably above their cost of capital of 6.63%, which is the first-order test of value creation — each is compounding, not merely turning the crank. On invested capital the three cluster in the mid-to-high teens to low-twenties, with JNJ's 21.5%, Merck's 18.0% and AbbVie's 15.1% all clearing the hurdle by a wide margin; AbbVie's is the lowest

+ The equity-return lines demand more care still. JNJ's reported ROE of 35.0% and ROA of 14.1% are FY2025 highs, but both are flattered by the talc-reserve reversal running through net income and should be read down toward the low-twenties ROE and high-single-digit ROA the franchise has historically produced. On that normalized basis Merck's 36.9% ROE and 14.4% ROA are the genuinely stronger of the

+ *Source: JNJ FY2025 10-K and prior filings; comparability notes in 5.7 — see Appendix A.1.*

+ JNJ's ROIC has been remarkably stable in the low-twenties across the five years, through the Kenvue separation and the talc-reserve cycle — a signature of a diversified franchise whose returns do not hinge on any single product or one year's accounting. ROE and ROA show far more volatility (ROE dipping toward the high-teens in FY2023 before the FY2025 rebound), but that volatility is a net-income-

+ | Metric | Johnson & Johnson | AbbVie Inc. | Merck & Co., Inc. |

+ | Net Debt / EBITDA | 0.9x | 2.7x | 1.3x |

+ | Total Debt / Equity | 0.6x | —ʰ | 0.9x |

+ | Interest Coverage | 26.0x | 5.7x | 15.6x |

+ | Current Ratio | 1.0x | 0.7x | 1.5x |

+ | FCF Margin | 20.9% | 29.1% | 19.0% |

+ *Source: Peer-company SEC filings (AbbVie FY2025 10-K; Merck FY2025 10-K); comparability notes in 5.7 — see Appendix A.1.*

+ *Footnote: ʰ AbbVie's Total Debt / Equity is not meaningful — the denominator (book equity) is negative — so leverage for that name is assessed on net-debt/EBITDA and interest coverage.*

+ This is where the three genuinely separate, and the spread is a real balance-sheet-quality differentiator rather than a comparability artifact. JNJ is one of only a handful of AAA-rated corporates in the world, and it earns the rating: net-debt/EBITDA of 0.9x is the lowest of the set by a wide margin, debt-to-equity is a conservative 0.6x, and interest coverage of 26.0x is comfortably the stronges

+ | Metric | Johnson & Johnson | AbbVie Inc. | Merck & Co., Inc. |

+ | EV/EBITDA | 20.8x | 21.4x | 13.0x |

+ | P/E | 24.6x | 104.3xⁱ | 17.6x |

+ | FCF Yield | 3.0% | 4.1% | 3.9% |

+ *Source: Peer-company SEC filings for net debt and share counts; equity prices market-sourced as of 2026-08-03 close; comparability notes in 5.7 — see Appendix A.1.*

+ *All peer valuation multiples are market-sourced (equity prices as of 2026-08-03 close) and subject to change with price movements.*

+ *Footnote: ⁱ AbbVie's GAAP P/E is not economically meaningful — the denominator (GAAP EPS) is suppressed by non-cash acquisition-accounting charges. Use EV/EBITDA and FCF yield for cross-company valuation.*

+ Given the earnings distortions catalogued above, EV/EBITDA and FCF yield are the honest cross-company yardsticks and P/E should be discounted at both ends: AbbVie's ~triple-digit GAAP P/E of 104.3x is a mechanical consequence of a suppressed denominator, not a statement about value, while JNJ's own 24.6x is understated in the opposite direction because the talc reversal inflated its earnings base.

+ *Source: JNJ FY2025 10-K (EBITDA) and period-end market prices; comparability notes in 5.7 — see Appendix A.1.*

+ Against its own history, JNJ's period-end EV/EBITDA has ranged through the mid-teens over the five years, troughing at 12.9x in FY2024 and re-rating to 16.2x at FY2025 year-end. The current-price multiple of 20.8x sits above that historical band, reflecting recent share-price appreciation — the stock is not cheap against its own past, and a premium of this size has to be earned by the balance-shee

+ | Metric | Johnson & Johnson | AbbVie Inc. | Merck & Co., Inc. |

+ | Days Sales Outstanding | 62 days | 75 days | 66 days |

+ | Days Inventory Outstanding | 161 days | 99 days | 148 daysʲ |

+ | Days Payables Outstanding | 135 days | — | 98 days |

+ | Cash Conversion Cycle | 88 days | — | 116 days |

+ | CapEx / Revenue | 5.1% | 2.0% | 6.3% |

+ *Source: Peer-company SEC filings (AbbVie FY2025 10-K; Merck FY2025 10-K); comparability notes in 5.7 — see Appendix A.1.*

+ *Footnotes: AbbVie's DPO and Cash Conversion Cycle are shown as not available — AbbVie reports trade payables combined with accrued liabilities on a single line, so they cannot be isolated cleanly and are omitted rather than computed off a contaminated denominator. ʲ Merck's inventory days understate true inventory because a material amount of inventory is classified in long-term other assets, off

+ The efficiency comparison mostly reflects business mix rather than working-capital skill, and it rewards a careful read because the headline lines pull in opposite directions. On collections, JNJ is the fastest of the set: days sales outstanding of 62 days undercuts both Merck's 66 days and AbbVie's 75 days — a modest but genuine edge. The standout on the other side is inventory: JNJ's 161 days of

+ **1. Business-mix mismatch (all metrics).** JNJ is pharma plus MedTech; AbbVie and Merck are pure-pharma. MedTech — roughly a third of JNJ's sales, at structurally lower margin and slower growth — drags JNJ's consolidated gross and EBITDA margins toward a blended average below a pure-pharma comparison, and lifts its inventory days and capital intensity. Do not read JNJ as "less profitable" than th

+ **2. GAAP net income is distorted three different ways (net margin, P/E, ROE, ROA).** JNJ's FY2025 net income is inflated by a talc-litigation reserve reversal, flattering its net margin, P/E, ROE, and ROA. AbbVie's is crushed by a large block of non-cash intangible amortization plus contingent-consideration remeasurement and acquired IPR&D, rendering its GAAP net margin and ~triple-digit P/E not

+ **3. AbbVie carries negative book equity (ROE, D/E, BVPS, gross margin).** An accumulated deficit from Allergan goodwill and sustained buybacks leaves AbbVie with negative total stockholders' equity, so its ROE, debt-to-equity, and book value per share are not meaningful and are reported as such rather than as spurious numbers (a naive ROE calculation returns an absurd figure). Separately, AbbVie'

+ **6. Working-capital and returns-basis comparability limits (DPO, CCC, inventory days, ROIC).** AbbVie reports trade payables combined with accrued liabilities on one line, so its DPO and cash-conversion cycle cannot be isolated cleanly and are omitted rather than computed off a contaminated denominator. Merck's current inventory excludes a material amount of inventory classified in long-term othe

+ **A note on patent cliffs.** All three face loss-of-exclusivity risk that colours the growth comparison and should be read alongside the multiples. JNJ faces Stelara biosimilar erosion, cushioned by Darzalex, Tremfya, Carvykti, and the MedTech portfolio. AbbVie is already absorbing Humira biosimilar erosion, with Skyrizi and Rinvoq as the offset — its FY2025 growth reflects the post-Humira inflect

+ Our fair value for Johnson & Johnson rests on four independent methods, equal-weighted at 25% each within every scenario to produce the composite fair value of $189.25. Each lens captures something the others cannot. The discounted-cash-flow method anchors on intrinsic value — the long-run unlevered cash the two operating segments generate, discounted at the company's cost of capital — and is by f

+ We deliberately set the 12-month target to the equal-weighted **composite** ($189.25) rather than to the DCF base alone, and the reason is a matter of intellectual honesty rather than convention. The DCF base of $225.44 is the single most generous leg in this analysis, and it is generous precisely because it leans on a discount rate that itself rests on a judgment call — a *normalized* beta of 0.5

+ | DCF (3 scenarios) | 25% | Intrinsic value from long-term unlevered free-cash-flow compounding; the most sensitive to the discount-rate and terminal assumptions, and the leg most dependent on the normalized-beta judgment |

+ | P/E Relative | 25% | Earnings-based and market-oriented; anchored to the large-cap pharma peer set |

+ | Scenario | Fair Value / Share | Upside / Downside vs. Current Price ($271.11) |

+ | Bear | $188.55 | Below the current price |

+ | Base | $225.44 | -16.8% |

+ | Bull | $271.83 | Only at the current price |

+ The DCF is built on operating earnings (EBIT → NOPAT → unlevered free cash flow), deliberately clean of the talc-reserve movements that whipsaw reported net income, and its terminal value is the **average** of a perpetuity-growth leg and an exit-EV/EBITDA leg. The base-case fair value of $225.44 sits -16.8% below the current price of $271.11: on disciplined operating cash flows and a normalized co

+ Two structural features of this DCF argue for reading it as an upper bound rather than a floor. First, the terminal value is 81% of enterprise value in the base case — a heavy dependence on assumptions that lie beyond the explicit forecast. Second, the model adds back all depreciation and amortization to cash flow, including roughly $4.6bn of recurring intangible amortization created by past acqui

+ Each relative method applies a through-cycle target multiple to the company's metric to derive a fair value per share. The implied fair values below are the base-case outputs that flow into the composite in 6.4 alongside the DCF. The target multiples were re-anchored for today's higher-rate environment — with the 10-year Treasury at 4.72%, a justified multiple compresses relative to the lower-rate

+ | P/E | 24.6x | 17.0x | $187.51 |

+ | EV/EBITDA | 20.8x | 13.5x | $171.97 |

+ | FCF Yield | 3.0% | 4.8% | $172.07 |

+ For a mature, cash-generative pharmaceutical-and-medtech franchise, **EV/EBITDA** is the most relevant single cross-check because it neutralizes the very different leverage and amortization loads across the peer set — JNJ's AAA balance sheet against AbbVie's Allergan debt and its enormous intangible amortization. The target of 13.5x, the low end of JNJ's own 13–15x through-cycle band, sits far bel

+ The **P/E** target of 17.0x is applied to FY2025 diluted EPS of $11.03, and this leg — $187.51 — is the most generous of the three relative methods for a reason the reader should weigh carefully. Reported GAAP EPS in FY2025 was *inflated* by a roughly $7bn non-cash reversal of the talc reserve, booked below operating profit; that reversal is the reason GAAP EPS this year sits even above management

+ | DCF | $188.55 | $225.44 | $271.83 |

+ | P/E Relative | $159.38 | $187.51 | $215.64 |

+ | EV/EBITDA Relative | $144.42 | $171.97 | $199.52 |

+ | FCF Yield | $149.63 | $172.07 | $202.44 |

+ | **Composite Fair Value** | **$160.50** | **$189.25** | **$222.36** |

+ The scenario weighting we attach to these outcomes is 25% / 50% / 25% across bear, base and bull. The base case carries the majority weight because it reflects the disciplined central assumptions; the tails are symmetric because the two swing factors — the discount rate and the terminal method — cut in both directions with roughly equal force.

+ | Scenario | Probability | Composite Fair Value | Reading vs. Current Price ($271.11) |

+ |---|---|---|---|

+ | Bear | 25% | $160.50 | Well below — a de-rating toward JNJ's normal multiples |

+ | Base | 50% | $189.25 | -30.2% — the 12-month target |

+ | Bull | 25% | $222.36 | Still below the current price |

+ *Source: FL valuation model (Valuation sheet) — see Appendix A.1–A.2.*

+ **Composite Fair Value (Base):** $189.25 | **Current Price:** $271.11 | **Implied Upside / Downside:** -30.2%

+ The composite base of $189.25 sits -30.2% below the current price — more conservative than the DCF alone, because the three relative methods each embed a de-rating toward JNJ's own normal multiples that the intrinsic method does not. The most telling feature of the table is that **even the bull composite of $222.36 remains below the current price**: there is no scenario in the composite framework

+ ## 6.5 The Discount Rate, Sensitivity, and the Reverse-DCF Cross-Check

+ **The beta decision — the single most important call in this valuation.** JNJ's freshly-measured 60-month beta is **0.245** (independent web sources show ~0.23). Plugged into the cost of equity as-is, that beta implies a required equity return of only about 5.8% — barely one percentage point above the 4.72% risk-free rate — and it drags the perpetuity discount rate to within roughly three points o

+ The reader should see how much the call hinges on this one input. Had we used the measured 0.245, the DCF would have inflated toward ~$275 and the composite would have risen to roughly **~$208** — the low beta would have quietly "explained away" the expensive price. That is the trap normalization avoids: at 0.245 the model would be reverse-engineering a justification for the market quote rather th

+ The base-case DCF is most sensitive to the two assumptions that drive the terminal value — the discount rate and the terminal growth rate — because the terminal is 81% of enterprise value. The first grid isolates the **perpetuity** leg across WACC (down the rows, increasing) and terminal growth (across the columns, increasing); the highest values sit top-right, the lowest bottom-left. The second g

+ **WACC × Terminal Growth Rate — DCF Fair Value / Share (perpetuity leg)**

+ | WACC \ TGR | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |

+ |---|---|---|---|---|---|---|---|

+ | 4.6% | 305.4 | 349.9 | 411.3 | 501.6 | 647.2 | 921.5 | 1,630.0 |

+ | 5.1% | 266.5 | 299.6 | 343.3 | 403.6 | 492.2 | 635.0 | 904.1 |

+ | 5.6% | 236.1 | 261.6 | 294.1 | 336.9 | 396.1 | 483.0 | 623.1 |

+ | 6.1% | 211.6 | 231.7 | 256.7 | 288.6 | 330.7 | 388.7 | 474.0 |

+ | 6.6% | 191.5 | 207.7 | 227.4 | 252.0 | 283.3 | 324.5 | 381.5 |

+ | 7.1% | 174.6 | 187.9 | 203.9 | 223.3 | 247.3 | 278.0 | 318.6 |

+ | 7.6% | 160.3 | 171.4 | 184.5 | 200.2 | 219.2 | 242.8 | 273.0 |

+ | 8.1% | 148.0 | 157.4 | 168.3 | 181.2 | 196.5 | 215.2 | 238.4 |

+ | 8.6% | 137.3 | 145.3 | 154.5 | 165.3 | 177.9 | 193.0 | 211.3 |

+ **WACC × Exit EV/EBITDA Multiple — DCF Fair Value / Share (exit leg)**

+ | WACC \ Exit EV/EBITDA | 7.5 | 9.5 | 11.5 | 13.5 | 15.5 | 17.5 | 19.5 |

+ |---|---|---|---|---|---|---|---|

+ | 4.6% | 137.2 | 164.1 | 191.0 | 218.0 | 244.9 | 271.8 | 298.7 |

+ | 5.1% | 134.1 | 160.4 | 186.7 | 213.0 | 239.3 | 265.6 | 291.9 |

+ | 5.6% | 131.1 | 156.8 | 182.5 | 208.2 | 233.8 | 259.5 | 285.2 |

+ | 6.1% | 128.2 | 153.3 | 178.4 | 203.5 | 228.5 | 253.6 | 278.7 |

+ | 6.6% | 125.4 | 149.9 | 174.4 | 198.9 | 223.4 | 247.9 | 272.4 |

+ | 7.1% | 122.7 | 146.6 | 170.5 | 194.4 | 218.4 | 242.3 | 266.2 |

+ | 7.6% | 120.0 | 143.4 | 166.7 | 190.1 | 213.5 | 236.9 | 260.2 |

+ | 8.1% | 117.4 | 140.2 | 163.1 | 185.9 | 208.7 | 231.6 | 254.4 |

+ | 8.6% | 114.8 | 137.2 | 159.5 | 181.8 | 204.1 | 226.4 | 248.8 |

+ *Source: FL valuation model (Valuation sheet) — see Appendix A.1–A.2.*

+ **Reverse-DCF cross-check — what the market is embedding.** Read the grids against the current price of $271.11 and the discount of the base case becomes concrete. On the perpetuity leg, at the 6.63% base WACC, the current price is reproduced only as terminal growth approaches the 3.0% column — above our 2.5% cap, which is itself already set near the ceiling of long-run US nominal GDP. Holding ter

+ **Rating:** REDUCE | **12-Month Price Target:** $189.25 | **Conviction:** Medium

+ We rate Johnson & Johnson **REDUCE** with a **Medium**-conviction 12-month target of $189.25, the equal-weighted composite fair value, against a current price of $271.11. The thesis in one sentence: this is a fortress franchise trading at a price that already pays for its durability twice over — at $271.11 the market prices JNJ well above the $189.25 composite (-30.2% downside), and every method i

+ This is a "priced-for-perfection, wait for a better entry" call rather than a distress case, and that is why conviction is **Medium** and not high. The quality is genuine: a AAA-rated, lightly-levered dividend king with a diversified two-segment model, a deep Innovative Medicine pipeline, and a dividend raised for more than six decades — characteristics that cushion the downside and make the reali

+ **Key Catalyst:** A definitive, court-approved, capped talc settlement that removes the litigation overhang — the single development that would most change the risk-reward and could support a re-rating toward the bull composite of $222.36.

+ **Key Risk:** An adverse talc outcome in the tort system — an uncapped, unreserved liability against which the company holds no product-liability insurance — compounded by STELARA biosimilar erosion outrunning the Innovative Medicine pipeline.

+ | 1 | A de-rating restores a margin of safety | Share price falls to within 5% of the $189.25 composite | Opportunistic |

+ | 2 | A definitive, capped talc settlement | A court-approved global resolution with a bounded cash cost | 12–24 months |

+ | 3 | Beta normalizes on a genuine, non-litigation basis | Measured 60-month beta reverts sustainably toward the 0.50 normalized anchor from the current 0.245, for two consecutive quarters | 12–24 months |

+ | 4 | Innovative Medicine absorbs the STELARA cliff | Segment operational growth stays positive through the biosimilar erosion | Through FY2027 |

+ | 5 | MedTech re-acceleration | MedTech operational growth sustained in the high single digits (>7%) | Through FY2027 |

+ | 1 | An adverse talc development in the tort system | A large adverse verdict or a settlement framework materially above the current reserve (a cash cost above ~$10bn) | Ongoing |

+ | 2 | STELARA erosion outruns the pipeline | Innovative Medicine operational growth turns negative | Through FY2027 |

+ | 3 | Further multiple expansion without earnings support | Forward P/E on normalized EPS re-rates above the current ~30.8x on flat operating earnings | Opportunistic |

+ | 4 | Debt-funded, dilutive M&A | An acquisition that lifts net-debt/EBITDA above the AAA-consistent range (roughly >1.5x) without a clear return case | Ongoing |

+ | 5 | IRA / drug-pricing pressure intensifies | Medicare price-negotiation and access pressure compress Innovative Medicine margins beyond the modelled path (EBITDA margin below the 34% floor) | Through FY2027 |

+ # Section 7 — Quarterly Update: Q2 2026

+ *This update covers Q2 2026 (the fiscal second quarter ended June 28, 2026). Johnson & Johnson has a December 52/53-week fiscal year-end. All standalone-quarter figures are as reported in the Q2 2026 Form 10-Q; year-over-year (YoY) comparisons are versus Q2 2025 and sequential (QoQ) comparisons versus Q1 2026. Page references throughout this section are the PDF pages of the filing copy on record,

+ **REDUCE**

+ | **Action** | REDUCE — the report-level rating, and this quarter does not change it |

+ | **Reason** | The quarter was operationally strong — revenue +6.6% YoY to $25,310.0M (operational +5.6% while absorbing a 4.6 pp STELARA biosimilar drag), EBIT +6.9% to $7,174.0M and standalone-quarter FCF conversion of 131.8% — but the call is valuation, not operations: at $271.11 against a composite fair value of $189.25, the implied return is -30.2%, and nothing in the quarter moves fair value

+ | **Thesis intact?** | YES — the REDUCE thesis is a *fully-valued fortress*, and the quarter confirmed both halves: the fortress (7.8% Innovative Medicine growth through the Stelara cliff, a 38.1% IM segment margin, net debt down 14.1% QoQ to $28,614.0M at 0.85× LTM EBITDA) and the full valuation (flat earnings per share, an uncapped talc tail, and a price 43% above composite fair value). Operatin

+ | **Trigger to revisit** | Upgrade to HOLD if the price falls to or below $189.25, or if the ovarian-cancer MDL is dismissed following the Motion to Show Cause granted in July 2026 *and* a comprehensive capped talc resolution lands within roughly the $3.7 billion reserved (10-Q pp. 61–62) — the single largest uplift to fair value available. Downgrade to SELL if the MDL causation rulings reverse ag

+ *Source: JNJ Form 10-Q for the fiscal second quarter ended June 28, 2026; FL valuation model (Valuation sheet) for the rating, fair-value and price references — see Appendix A.1–A.2.*

+ | Metric | Q2 2026 | Q2 2025 | YoY Δ | Q1 2026 | QoQ Δ |

+ | **EBIT ($M)** ᵃ | $7,174.0M | $6,710.0M | +6.9% | $6,359.0M | +12.8% |

+ YoY Δ is computed as (CQ - PYSQ) / |PYSQ| × 100 — revenue: (25,310 - 23,743) / 23,743 × 100 = +6.6%. QoQ Δ is computed as (CQ - PQ) / |PQ| × 100 — revenue: (25,310 - 24,062) / 24,062 × 100 = +5.2%. Margins are computed as metric / revenue × 100 — gross margin CQ: 17,259 / 25,310 × 100 = 68.2% (this ties exactly to the filing's own "Percent to Sales" column, 10-Q p. 12); EBITDA margin CQ: 9,133 / 2

+ ᵃ Johnson & Johnson does not present an operating-income subtotal on the face of its earnings statement. EBIT here is the workbook's consistent definition — gross profit less SG&A less R&D: 17,259 - 6,432 - 3,653 = $7,174.0M in Q2 2026 (Q2 2025: 16,115 - 5,889 - 3,516 = $6,710.0M) — *excluding* interest, Other (income) expense net, and the Restructuring line, which the filing reports below these o

+ *Source: JNJ Q2 2026 Form 10-Q — Consolidated Statements of Earnings, fiscal second quarter (10-Q p. 12); fiscal six months (10-Q p. 13). The Q1 2026 column is the FL workbook quarterly series (Data sheet, col. 22), which reconciles exactly to the six-month statement less the second-quarter column on every line — revenue 49,372 - 25,310 = 24,062; gross profit 33,215 - 17,259 = 15,956; net earnings

+ **Segment results — income before tax is the Company's stated segment profit measure**

+ | Segment | Sales Q2 2026 ($M) | Sales Q2 2025 ($M) | YoY Δ | Income before tax Q2 2026 ($M) | Q2 2025 ($M) | YoY Δ | Margin Q2 2026 | Q2 2025 | Δ pp |

+ |---|---|---|---|---|---|---|---|---|---|

+ | Innovative Medicine | 16,384 | 15,202 | +7.8% | 6,249 | 5,552 | +12.6% | 38.1% | 36.5% | +1.6 pp |

+ | MedTech | 8,926 | 8,541 | +4.5% | 1,177 | 1,204 | -2.2% | 13.2% | 14.1% | -0.9 pp |

+ | Segment total | 25,310 | 23,743 | +6.6% | 7,426 | 6,756 | +9.9% | 29.3% | 28.5% | +0.8 pp |

+ | Expenses not allocated to segments ᵇ | — | — | — | (679) | (265) | +156.2% | — | — | — |

+ | **Consolidated pre-tax** | **$25,310.0M** | **$23,743.0M** | **+6.6%** | **6,747** | **6,491** | **+3.9%** | **26.7%** | **27.3%** | **-0.6 pp** |

+ ᵇ Unallocated amounts comprise interest (income)/expense, certain litigation expenses and general corporate items; the Q2 2026 figure **includes $0.4 billion of charges for talc matters** (Q2 2025: no talc charge disclosed in the equivalent footnote). This one line is why a +9.9% segment-level profit advance became a +3.9% consolidated pre-tax advance (10-Q p. 56).

+ The two segment margins moved in opposite directions for identifiable reasons: Innovative Medicine's +1.6 pp came from favourable securities fair-value changes, lower Intra-Cellular integration costs and R&D phasing, *net of* $0.2 billion of new supply-chain restructuring and Stelara mix; MedTech's -0.9 pp is dominated by **$0.3 billion of Orthopaedics-separation costs that did not exist in Q2 202

+ *Source: JNJ Q2 2026 Form 10-Q — Note 9, Segments of Business (10-Q p. 56) and MD&A segment analysis (10-Q p. 90).*

+ **Revenue:** Sales of $25,310.0M grew +6.6% YoY — +5.6% operational and +1.0% currency — while absorbing an approximate **4.6 pp drag on worldwide operational growth from the STELARA biosimilar decline**; acquisitions/divestitures were a net -0.1% (10-Q p. 70). The quarter's defining offset sits inside Immunology: STELARA fell -55.2% to $740M (a $913M loss of quarterly revenue) while TREMFYA grew

+ **Cost and margin:** Cost of products sold of $8,051.0M against $7,628.0M a year ago rose +5.5%, one point slower than the +6.6% revenue growth, taking the COGS ratio to 31.8% from 32.1% and gross margin up +0.3 pp to 68.2% — operational drivers and favourable currency, *net of* unfavourable Stelara mix and **tariffs in the MedTech business**, with amortization of intangibles inside COGS easing to

+ **Below the line:** Everything that separates flat net income from +6.9% EBIT growth sits in three lines. Net interest was a $62M expense versus $48M — interest expense of $281.0M actually *fell* from $308M on a lower average rate, but interest income fell faster ($219M vs $260M) on a lower average cash balance (10-Q pp. 12, 86). Other (income) expense, net swung to $331M of expense from $107M — t

+ | Metric | Q2 2026 | Q2 2025 | YoY Δ | Q1 2026 | QoQ Δ |

+ | Net Debt / LTM EBITDA | 0.85× ᶜ | — | — | — | — |

+ | CapEx ($M) ᵈ | $1,321.0M | $1,043.0M | +26.7% | $1,049.0M | +25.9% |

+ | Dividends Paid ($M) ᵈ | $3,227.0M | $3,129.0M | +3.1% | $3,131.0M | +3.1% |

+ YoY and QoQ percentages use the same formulas as 7.1 — net debt YoY: (28,614 - 32,184) / |32,184| × 100 = -11.1%; net debt QoQ: (28,614 - 33,299) / |33,299| × 100 = -14.1%.

+ ᶜ *Net Debt / LTM EBITDA: LTM EBITDA = Q3 2025 $8,873.0M + Q4 2025 $7,293.0M + Q1 2026 $8,363.0M + Q2 2026 $9,133.0M = $33,662.0M (the two 2025 quarters are taken from the workbook's standalone quarterly series, Data sheet row 20, cols 20–21, because the section-7 data pack carries only the CQ/PYSQ/PQ columns). Net Debt $28,614.0M / $33,662.0M = **0.85×**. Net debt reconciles exactly to the filing

+ ᵈ CapEx and dividends are stored as positive magnitudes in the workbook and shown as such here; both are cash **outflows**. A positive Δ therefore means a larger outflow. Both tie to the filing: six-month capex of $2,370M = $1,049.0M + $1,321.0M, and six-month dividends of $6,358M = $3,131.0M + $3,227.0M at $1.30 then $1.34 per share (10-Q pp. 16, 20–21).

+ *Source: JNJ Q2 2026 Form 10-Q — Consolidated Balance Sheets (10-Q p. 11) and Consolidated Statements of Cash Flows (10-Q pp. 20–21). Standalone-quarter cash-flow figures are derived by the pipeline from the six-month statement less the prior 10-Q's three-month statement (OCF: 11,130 - 2,514 = 8,616).*

+ **Balance sheet note:** The headline is deleveraging — net debt fell 14.1% sequentially to $28,614.0M on the quarter's $8,616M of operating cash flow — but the composition shifted markedly toward short-term funding: loans and notes payable rose to $11,692M from $8,495M at year-end (+37.6%), **including commercial paper of $9.9 billion, up from $6.5 billion at December 28, 2025**, while long-term d

+ **Cash flow note:** FCF conversion = FCF / Net Income = 7,295 / 5,534 = **131.8%** in Q2 2026, against 51.2% in Q2 2025 and 28.0% in Q1 2026. The dramatic YoY improvement is real but flattered by the base: the prior-year six months carried a $6,194M increase in other assets and a $5,926M decrease in other liabilities — the cash-flow shadow of the talc-era balance-sheet unwind — versus +$1,299M and

+ **Forensic observations (read from the filing, in order of importance):**

+ 1. **First-half capital returns exceeded free cash flow, and commercial paper funded the difference.** Dividends of $6,358M plus share repurchases of $4,249M total $10,607M of six-month returns against six-month FCF of $8,760M ($11,130M OCF - $2,370M capex) — a $1.85 billion overrun. Over the same six months, net short-term debt proceeds were +$3,469M ($13,146M drawn, $9,677M repaid) while $2,003M

+ 2. **The talc reserve is being rebuilt in $0.4 billion quarterly instalments, and the cash demands are scheduled.** After the ~$7.0 billion reversal in Q1 2025, charges for talc matters were $0.4 billion this quarter and $0.8 billion for the six months (10-Q p. 56); the reserve stands at ~$3.7 billion present value, ~40% current, against approximately 76,000 pending U.S. claimants (10-Q p. 61). Ma

+ 3. **The buyback is not a buyback.** Of the $4,253M of six-month repurchases in the equity statement, only $219M occurred in Q2 (10-Q p. 16); the Part II issuer-purchases table shows just 970,250 shares bought in the quarter at an average $229.54, **all under systematic plans to meet compensation-program needs, with no publicly-announced repurchase program in place** (the "shares that may yet be p

+ 4. **Restructuring is larger than the Restructuring line.** Total program expense in the quarter was $276M — a new Innovative Medicine supply-chain program ($200M, mostly asset impairments, of an estimated $650–750M through 2029), Surgery ($59M) and Orthopaedics ($17M) — but only $34M appears on the face-of-P&L Restructuring line; $35M sits in cost of products sold and $207M in Other (income) expe

+ 5. **Intangibles are amortising down with no impairment activity:** intangible assets fell to $48,229M from $50,403M at year-end and goodwill was stable at $48,479M (movement almost entirely currency, -$296M); the last annual impairment test was Q4 2025 and no interim test was triggered; scheduled amortization is ~$5.1 billion for 2026 stepping down to ~$3.5 billion by 2030 (10-Q p. 24). Six-month

+ *All twelve notes to the consolidated financial statements were read in full in this session, together with the five primary statements, the whole of Item 2 (MD&A), Items 3 and 4, and Part II Items 1, 2, 5 and 6. Page references are PDF pages of the filing copy. Where a note carries both-period figures, the change assessment below is made from the amounts printed in this filing; balance-sheet note

+ **Note 1 — Basis of presentation, accounting standards, supplier finance (10-Q p. 22)**

+ Normal recurring adjustments only. One standard adopted in fiscal 2026 — ASU 2025-07 (derivative scope exception) — with no material impact, and no new material standards pending. The supplier finance program stands at $0.7 billion of confirmed obligations (year-end: $0.8 billion), 90-day general payment terms, presented inside accounts payable. Confirmed unchanged in structure vs year-end and imm

+ **Note 2 — Inventories (10-Q p. 22)**

+ Total inventories $15,144M vs $14,191M at year-end (+6.7%): raw materials $2,515M (-0.6%), goods in process $4,224M (+10.3%), finished goods $8,405M (+7.3%). The build is broadly in line with 8.2% six-month sales growth and consistent with the MedTech tariff environment favouring inventory positioning; not a red flag, monitored.

+ **Note 3 — Intangible assets and goodwill (10-Q p. 24)**

+ Treated in forensic observation 5 above. Definite-lived intangibles net $30,764M (patents/trademarks $24,815M + customer relationships $5,949M), indefinite-lived trademarks $1,744M and IPR&D $15,721M; goodwill $48,479M split Innovative Medicine $14,755M / MedTech $33,724M. Annual impairment test completed Q4 2025; movement in the half is amortization and currency only. Amortization inside COGS: $1

+ **Note 4 — Fair value measurements, derivatives, debt and cash detail (10-Q pp. 26–41)**

+ Three items matter. (i) **Debt structure:** the current-debt balance of $11,692M includes **$9.9 billion of commercial paper** (3.68% weighted-average rate, ~2-month weighted maturity) versus $6.5 billion at year-end; non-current debt of $37,344M carries a 3.57% weighted-average effective rate and a fair value of $35,408M — $1.9 billion *below* carrying value (year-end: $1.7 billion below) (10-Q p

+ **Note 5 — Income taxes (10-Q p. 41)**

+ Six-month effective rate 15.5% vs 17.8%. The disclosed drivers: the prior year absorbed the ~$7.0 billion talc-reserve reversal recorded at ~22%; the prior year also benefited from uncertain-tax-position releases on statute expirations; and 2026 carries share-based-compensation windfall benefits that reduced the six-month rate by 2.9% (2025: 0.3%) — a benefit that exists only because the stock ral

+ **Note 6 — Pensions and other benefit plans (10-Q p. 42)**

+ Retirement plans swung to a net periodic *credit* of $19M in the quarter (Q2 2025: $16M cost) on expected asset returns of $638M outrunning service and interest cost; other benefit plans cost $155M (vs $138M). Six-month contributions were modest: $70M U.S., $10M international. Non-service components sit in Other (income) expense — part of the $0.2 billion favourable "employee benefit related" line

+ **Note 7 — Accumulated other comprehensive income (10-Q p. 43)**

+ AOCI improved to $(13,951)M from $(14,930)M at year-end: currency translation +$1,538M (the dollar weakened), employee benefit plans +$82M, derivatives -$641M. The $0.9 billion after-tax deferred net loss on derivatives will substantially reclassify to earnings over the next 12 months (10-Q p. 26) — a known, modest headwind to reported gross margin as hedges roll. Routine; confirmed consistent wit

+ **Note 8 — Earnings per share (10-Q p. 43)**

+ The quarter's quiet governance datum, treated in forensic observation 3: diluted shares 2,440.1M vs 2,419.1M (+0.9%); potential option shares 92.9M vs 64.6M; anti-dilutive exclusions collapsed to 6.8M from 66.3M. Basic EPS was flat at $2.30; the entire diluted-EPS decline (-0.9%) is the option overhang coming into the money. Cover page: 2,409,898,597 shares outstanding at July 17, 2026 (10-Q p. 2)

+ **Note 9 — Segments of business and geographic areas (10-Q pp. 44–57)**

+ Two reportable segments, unchanged; segment income before tax remains the CODM's stated measure, and the full product-level sales table is disclosed (treated in 7.1–7.2). Beyond the headline: identifiable assets are Innovative Medicine $78,856M, MedTech $86,581M, general corporate $35,624M; six-month segment capex shows Innovative Medicine surging to $1,161M from $687M (+69.0% — capacity investmen

+ **Note 10 — Acquisitions, divestitures and other arrangements (10-Q pp. 57–59)**

+ Three live items. (i) **Firefly Bio**: definitive agreement announced June 8, 2026 — $1 billion cash for a degrader-antibody-conjugate platform, closing expected fiscal Q3 2026, to join Innovative Medicine. (ii) **2025 transactions**: Halda Therapeutics ($3.05 billion, December 2025 — $2.8 billion of the price sits in acquired IPR&D, i.e., pre-revenue) and Intra-Cellular ($14.5 billion, April 2025

+ **Note 11 — Legal proceedings (10-Q pp. 61–66)** — see the consolidated contingencies entry below for the full docket

+ The talc architecture after the third bankruptcy dismissal: all talc liabilities sit in Red River Talc LLC and Pecos River Talc LLC, litigation is back in the tort system, ~$7.0 billion of reserve was reversed in Q1 2025, and the present-value reserve is now **~$3.7 billion (≈40% current), covering executed settlements, defense and other costs — not the unresolved claim body of ~76,000 plaintiffs*

+ **Note 12 — Restructuring (10-Q pp. 66–67)**

+ Treated in forensic observation 4. Three programs running: the **new** Innovative Medicine supply-chain program (initiated this quarter, $200M recorded, $650–750M estimated through 2029), Surgery ($59M in the quarter; ~$0.3 billion recorded of an estimated $0.6–0.7 billion, substantially complete end-2026) and Orthopaedics ($17M; ~$0.8 billion recorded of ~$1.0 billion, complete Q4 2026 — clearing

+ **Related-party transactions (10-Q pp. 22, 34, 57–59, 88)**

+ Johnson & Johnson has **no controlling shareholder, and this 10-Q contains no related-party transactions note** — no related-party caption appears in the notes (10-Q pp. 22–67), consistent with a widely-held S&P-10 issuer. This is documented rather than assumed. The filing's nearest related-interest disclosures, each quantified: (i) **JJDC** (Johnson & Johnson Innovation — JJDC, Inc., the wholly-o

+ **Contingencies and litigation (10-Q pp. 61–66)**

+ Every named open matter, with quarter status: (1) **Talc product liability** — ~76,000 U.S. plaintiffs; reserve ~$3.7 billion PV (~40% current); Q2 charge $0.4 billion, 1H $0.8 billion; MDL Motion to Show Cause granted July 2026 (above). Amount at stake beyond accrual: not estimable. (2) **Talc securities class action** (D.N.J., 2018) — class certified, certiorari denied April 2026, expert discove

+ **Subsequent events (disclosed within the body of the filing — there is no dedicated subsequent-events note)**

+ The notes run 1 through 12 with no subsequent-events caption; post-quarter facts disclosed elsewhere in the filing: (i) **July 15, 2026 — the Board declared the regular $1.34 quarterly dividend**, payable September 8, 2026 (10-Q p. 96); (ii) **July 2026 — the ovarian MDL court granted the Company's Motion to Show Cause**, and the Special Master issued the asbestos-testing report granting the Compa

+ **Guidance status (10-Q, Item 2 — none given)**

+ Consistent with 10-Q practice, the filing contains no revenue or EPS guidance; the forward-looking content is directional and almost all of it points down for specific franchises: STELARA biosimilars "will continue to negatively impact" sales; **SIMPONI biosimilars entered the European market in the second quarter of 2026, with a potential U.S. entrant later in 2026** — "this will likely result in

+ ## 7.5 What Changed This Quarter

+ - **The Stelara cliff is now fully absorbed in-quarter by its own successor.** STELARA fell -55.2% to $740M (-$913M YoY) while TREMFYA grew +72.5% to $2,046M (+$860M) — a net -$53M — and total Innovative Medicine still grew +7.8% with segment margin *up* 1.6 pp to 38.1% (10-Q pp. 46, 56). This is the strongest evidence yet for the "fortress" half of the thesis: the worst patent cliff in the compan

+ - **But the next erosion wave started inside this same quarter.** SIMPONI biosimilars entered Europe in Q2 2026 (a $618M-per-quarter franchise, already -10.5%), a U.S. entrant is possible later in 2026, and OPSUMIT generics entered the U.S. late in the quarter ($602M per quarter, +3.4%) (10-Q pp. 46, 48, 78). Roughly $1.2 billion of quarterly revenue moved from "stable" to "eroding" within the qua

+ - **Talc turned two-sided.** New and favourable: plaintiffs withdrew two specific-causation experts, and in July 2026 the MDL court granted the Company's Motion to Show Cause why the ovarian MDL should not be dismissed (conference August 2026) — the first genuine dismissal path since the bankruptcy strategy failed (10-Q p. 62). Unchanged and unfavourable: ~76,000 claimants, a ~$3.7 billion reserve

+ - **Net income quality inverted: operations up, headline flat.** EBIT +6.9% became net income -0.1% through a $224M higher Other-expense line (talc $0.4 billion, Orthopaedics-separation $0.2 billion, restructuring $0.2 billion) and a tax rate of 18.0% vs 14.7% (10-Q pp. 12, 41, 88). The 2026 tax rate also leans on a 2.9 pp share-price-dependent SBC benefit (six-month basis) that will not repeat me

+ - **A new $650–750M supply-chain restructuring opened in Innovative Medicine** ($200M charged this quarter, mostly asset impairments, running to 2029), while Innovative Medicine capex surged +69.0% to $1,161M in the half — the segment is simultaneously writing down old capacity and building new (10-Q pp. 57, 66).

+ - **Capital returns ran $1.85 billion ahead of free cash flow in the half, funded at the short end**: dividends $6,358M (+3.9% YoY, quarterly rate raised to $1.34 from $1.30) plus $4,249M of repurchases against $8,760M of FCF, with commercial paper up $3.4 billion to $9.9 billion and a new $12.5 billion 364-day facility behind it (10-Q pp. 20–21, 41, 96). Leverage remains a non-issue at 0.85× LTM

+ - **Dilution is now visible in the print.** Diluted shares +0.9% YoY turned flat net income into a -0.9% EPS decline; the option overhang is 92.9M shares, anti-dilutive exclusions collapsed from 66.3M to 6.8M, and there is no open-market repurchase program to absorb it (10-Q pp. 43, 99).

+ - **Litigation cash outflows are recurring, not contingent:** $0.8 billion Auris judgment paid in January 2026; ~$0.9 billion of opioid settlement payments still ahead; ~$1.5 billion of the talc reserve is current (10-Q pp. 61, 65, 96).

+ ---

+ ## 7.6 Portfolio Decision

+ **Why REDUCE:**

+ The rating is REDUCE with a composite fair value of $189.25 against a $271.11 price, and this quarter — deliberately — does not change it, because everything the quarter did well was already the expensive part of the story. Operationally it was close to flawless: revenue +6.6% to $25,310.0M through a 4.6 pp Stelara drag, EBIT +6.9% to $7,174.0M at a held 28.3% margin, TREMFYA replacing STELARA dol

+ **What would change this view:**

+ - **Upgrade condition (to HOLD, or better):** the price falling to or below $189.25, restoring a neutral implied return; or a structural repricing event — dismissal of the ovarian MDL following the August 2026 case-management conference combined with a comprehensive, court-durable talc resolution capped in the region of the ~$3.7 billion reserved — which would remove the largest unpriced tail and

+ - **Downgrade condition (to SELL):** an adverse general-causation ruling in the ovarian MDL or a resumption of nine-figure talc verdicts, converting the $0.4 billion quarterly re-accrual into another multi-billion step-change; Innovative Medicine operational growth turning negative as the second erosion wave compounds the Stelara decline; or the MedTech margin falling below 12% while separation co